Early detection program for prostate cancer: results and identification of high-risk patient population.

Three hundred sixty-two men underwent transrectal ultrasound of the prostate (TRUS), digital rectal examination (DRE), and serum prostate-specific antigen (PSA) determination as part of an early detection program for prostate cancer. Thirty-seven (10%) cancers were detected. DRE had the highest sensitivity and specificity, 89 percent and 84 percent, respectively. TRUS and PSA had comparable sensitivities (84% and 81%) and specificities (82% and 82%). The positive predictive values of DRE, TRUS, and PSA determination were 39 percent, 35 percent, and 33 percent, respectively. We found a cancer detection rate of 16 percent among patients with symptoms of bladder outlet obstruction and 5 percent in patients without these symptoms. The detection rate was 36 percent for physician-referred patients and 3 percent for self-referred patients. This suggests to us that at the present time the best utilization of medical resources to increase prostate cancer detection is to educate men to have annual medical evaluations by primary-care physicians who are encouraged to incorporate risk assessment and screening DRE as part of their routine practice. Any man with either abnormal findings on examination or increased risk should be referred to a urologist for further evaluation.

[1]  M. Terris,et al.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.

[2]  W. Whitmore Natural history and staging of prostate cancer. , 1984, The Urologic clinics of North America.

[3]  G. Murphy,et al.  Prostatic evaluation by transrectal sonography: criteria for diagnosis of early carcinoma. , 1986, Radiology.

[4]  H. Watanabe,et al.  Comparison of digital examination and transrectal ultrasonography for the diagnosis of prostatic cancer. , 1986, The Journal of urology.

[5]  J. Drago,et al.  Transrectal ultrasonography. Early experience with use as prostate cancer detection tool. , 1989, Urology.

[6]  A. Rademaker,et al.  Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. , 1990, The Journal of urology.

[7]  G. Murphy,et al.  Prostate cancer in blacks: An update from the American college of surgeons' patterns of care studies , 1989, Journal of surgical oncology.

[8]  F. Lee,et al.  Transrectal ultrasound in the diagnosis of prostate cancer: Location, echogenicity, histopathology, and staging , 1986, The Prostate.

[9]  S. Torp-Pedersen,et al.  Prostate Cancer: Comparison of Transrectal US and Digital Rectal Examination for Screening , 1988, Radiology.

[10]  B. Hulka Cancer screening degrees of proof and practical application , 1988, Cancer.

[11]  C. Boring,et al.  Cancer statistics, 1990 , 1990, CA: a cancer journal for clinicians.

[12]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.

[13]  R. Joseph Babaian,et al.  The role of prostate‐specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy , 1991, Cancer.

[14]  D. Siders,et al.  Transrectal biopsy of the prostate guided with transrectal US: longitudinal and multiplanar scanning. , 1989, Radiology.

[15]  Y. Tanahashi,et al.  Clinical evaluation of inside echo patterns in gray scale prostatic echography. , 1980, The Journal of urology.

[16]  Motonao Tanaka,et al.  [Diagnostic application of ultrasonotomography to the prostate]. , 1968, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[17]  G. Murphy,et al.  The national survey of prostate cancer in the United States by the American College of Surgeons. , 1982, The Journal of urology.

[18]  H H Holm,et al.  Major complications and deaths due to interventional ultrasonography: A Review of 8000 cases , 1990, Journal of clinical ultrasound : JCU.